At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 124 enrolled
Drug / intervention
Garadacimab, Factor XIIa Antagonist Monoclonal Antibody +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)
In Brief
A Phase 2 clinical trial evaluating Garadacimab, Factor XIIa Antagonist Monoclonal Antibody and Placebo for Coronavirus Disease 2019 (COVID-19). Completed, enrolled 124 participants across 14 sites.
Detailed Summary
This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC) treatment, in patients with Coronavirus disease 2019 (COVID 19)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronavirus Disease 2019 (COVID-19)
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJul 2020
Primary CompletionJan 2021
TodayJul 2026
First PostedJun 1, 2020
Enrollment StartJul 1, 2020
Primary CompletionJan 12, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.1 years ago
Interventions
Garadacimab, Factor XIIa Antagonist Monoclonal Antibodybiological
Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously
Placebodrug
CSL312 diluent administered intravenously